Highlight
1. Edoxaban showed comparable efficacy to warfarin in preventing stroke or systemic embolism early after surgical bioprosthetic valve replacement.
2. Safety analysis revealed no fatal bleeding or intracranial hemorrhage in patients on edoxaban, contrasting with one fatal intracranial hemorrhage in the warfarin group.
3. The incidence of intracardiac thrombus was zero in the edoxaban group but occurred at 1% in the warfarin group.
4. These findings suggest edoxaban as a feasible anticoagulant alternative within three months post-bioprosthetic valve surgery.
